Skip to main navigation Skip to search Skip to main content

Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials

Research output: Contribution to journalReview articlepeer-review

15 Downloads (Pure)

Abstract

In randomized controlled trials, investigators often explore the possibility that the treatment effects differ between subgroups (eg, women vs men, old vs young, more versus less severe disease). Investigators often inappropriately claim subgroup effects (also called "effect modification" or "interaction") when the likelihood of a true effect modification is low. Criteria for assessing the credibility of subgroup analyses, nicely summarized in a formal Instrument for Assessing the Credibility of Effect Modification Analyses (ICEMAN), include investigator postulation of a priori hypotheses with a specified direction; support from prior evidence; a low likelihood that chance explains the apparent subgroup effect; and only testing a small number of subgroup hypotheses. PATIENT SUMMARY: Randomized clinical trials often use subgroup analyses to explore whether a treatment is more or less effective in a particular patient subgroup (eg, women vs men, old vs young). In this mini-review, we explore the common pitfalls of subgroup analyses.

Original languageEnglish
Pages (from-to)1237-1239
Number of pages3
JournalEuropean Urology Focus
Volume7
Issue number6
Early online date20 Oct 2021
DOIs
Publication statusPublished - Nov 2021

Keywords

  • Effect modification
  • Evidence-based medicine
  • Interaction
  • Subgroup analyses

Fingerprint

Dive into the research topics of 'Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials'. Together they form a unique fingerprint.

Cite this